Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer

By sjmartinez • February 2, 2024

Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugère C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. J Clin Oncol. 2024 Feb 1:JCO2301214. doi: 10.1200/JCO.23.01214. Epub ahead of print. PMID: 38301187.

Tags: Hematology/Oncology, Publications

Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution

Zhang R, Qi J, McKasson M, Choi J, Gutierrez V, Brennan C, Hong S, Chour W, Ng RH, Xie J, Yuan D, Webster A, Sidhu[...]

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy

Shachar E, Rotkop G, Haas R, Frankenthal R, Kamara D, Demirjian M, Kwan L, Cummings S, Roscow B, Salani R, Spellman PT, Karlan B, Chase[...]

Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care Coordination in Safety-Net Systems

Tupper HI, Doo FX, Lin Y, Flores EJ, Salinas DA, Cummings AL, Ryan GW, Revels SL. Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care[...]